Switzerland Buys 6 Million Doses of Maryland-based COVID-19 Vaccine Candidate

Maryland-based Novavax, Inc. announced that the company had executed a binding Heads of Terms agreement with Switzerland's government to supply six million doses of its protein-based COVID-19 vaccine candidate NVX-CoV2373. The final agreement terms and delivery date are pending.

Novavax previously announced a similar agreement with Canada.

“The government of Switzerland is working proactively to ensure a sufficient supply of our vaccine that could protect its citizens from COVID-19,” said John J. Trizzino, Chief Commercial Officer and Chief Business Officer of Novavax, in a press statement issued on February 3, 2021. “Addressing this global public health crisis requires collaboration, and we appreciate their partnership to provide an urgently needed vaccine to stem the pandemic.”

NVX-CoV2373 is a prefusion protein coronavirus vaccine candidate made using Novavax’s proprietary nanoparticle technology, Matrix-M, an adjuvant to enhance immune responses and stimulate high levels of neutralizing antibodies. It is the first vaccine to demonstrate clinical efficacy against the original strain of COVID-19 and both of the rapidly emerging variants in the United Kingdom and South Africa.